EHA Update 2017 New Data on the Benefits of Novartis Ruxolitinib (Jakavi®) in Polycythemia vera and Myelofibrosis

被引:0
|
作者
不详
机构
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:372 / 372
页数:1
相关论文
共 50 条
  • [22] Tuberculosis and atypical mycobacterial infections in ruxolitinib-treated patients with primary or secondary myelofibrosis or polycythemia vera
    Lescuyer, Sylvain
    Ledoux, Marie-Pierre
    Gravier, Simon
    Natarajan-Ame, Shanti
    Duval, Celine
    Maloisel, Frederic
    Mauvieux, Laurent
    Toussaint, Elise
    Fornecker, Luc-Matthieu
    Herbrecht, Raoul
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2019, 80 : 134 - 136
  • [23] Efficacy and Safety of Single-Agent Ruxolitinib Therapy for Myelofibrosis and Polycythemia Vera: A Meta-Analysis
    Zhang, Shijia
    Wang, Yucai
    Sanchez, Larysa
    Duma, Narjust
    Chang, Victor
    BLOOD, 2015, 126 (23)
  • [24] Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study
    Sorensen, Anders Lindholm
    Mikkelsen, Stine Ulrik
    Knudsen, Trine Alma
    Bjorn, Mads Emil
    Andersen, Christen Lykkegaard
    Bjerrum, Ole Weis
    Brochmann, Nana
    Patel, Dustin Andersen
    Gjerdrum, Lise Mette Rahbek
    El Fassi, Daniel
    Kruse, Torben A.
    Larsen, Thomas Stauffer
    Mourits-Andersen, Hans Torben
    Nielsen, Claus Henrik
    Ellervik, Christina
    Pallisgaard, Niels
    Thomassen, Mads
    Kjaer, Lasse
    Skov, Vibe
    Hasselbach, Hans Carl
    HAEMATOLOGICA, 2020, 105 (09) : 2262 - 2272
  • [25] Phase I Study of Ruxolitinib in Combination with Abemaciclib for Patients with Primary or Post-Polycythemia Vera/ Essential Thrombocythemia Myelofibrosis
    Bewersdorf, Jan Philipp
    Verstovsek, Srdan
    Derkach, Andriy
    Masarova, Lucia
    Pemmaraju, Naveen
    Stein, Eytan
    Mauro, Michael
    Rampal, Raajit K.
    Bose, Prithviraj
    BLOOD, 2022, 140 : 6844 - 6846
  • [26] A phase I study of ruxolitinib in combination with abemaciclib for patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis
    Bewersdorf, Jan Philipp
    Verstovsek, Srdan
    Derkach, Andriy
    Masarova, Lucia
    Pemmaraju, Naveen
    Stein, Eytan M.
    Mauro, Michael J.
    Rampal, Raajit
    Bose, Prithviraj
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [27] A 10-year retrospective cohort study of ruxolitinib and association with nonmelanoma skin cancer in patients with polycythemia vera and myelofibrosis
    Lin, John Q.
    Li, Shirley Q.
    Li, Shufeng
    Kiamanesh, Eileen F.
    Aasi, Sumaira Z.
    Kwong, Bernice Y.
    Chang, Anne Lynn Su
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 86 (02) : 339 - 344
  • [28] A phase I study of ruxolitinib in combination with abemaciclib for patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis
    Bewersdorf, Jan P.
    Verstovsek, Srdan
    Derkach, Andriy
    Masarova, Lucia
    Pemmaraju, Naveen
    Stein, Eytan M.
    Mauro, Michael
    Rampal, Raajit
    Bose, Prithviraj
    CANCER RESEARCH, 2023, 83 (08)
  • [29] A Phase I Study of Ruxolitinib in Combination with Abemaciclib for Patients with Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
    Bewersdorf, Jan Philipp
    Derkach, Andriy
    Masarova, Lucia
    Pemmaraju, Naveen
    Stein, Eytan M.
    Mauro, Michael
    Rampal, Raajit K.
    Bose, Prithviraj
    BLOOD, 2023, 142
  • [30] Compassionate Use Program (CUP) with Ruxolitinib in Mexican Patients with Primary Myelofibrosis (PMF), Post - Polycythemia, Vera Myelofibrosis (PPV - MF), and Post Essential Thrombocythemia Myelofibrosis (PET - MF)
    Vargas, Pablo
    Ovilla, Roberto
    Alvarado, Martha
    Lopez, Manuel
    Hurtado Monroy, Rafael
    Carlos Solis, Juan
    Limon, Alejandro
    Agreda, Gladys
    Silva, Salvador
    Julio Kassack, Juan
    Zavala, Saida
    Aguilar, Carlos
    Baez, Enrique
    Barrera, Esperanza
    Osuna, Antonio
    Morales, Javier
    Herrera, Aquileo
    BLOOD, 2012, 120 (21)